Memorial Sloan Kettering Cancer Center Issues Statement on First Half 2026 Financial Results

Memorial Sloan Kettering Cancer Center (MSK) issued the following statement regarding its financial results for the first two quarters of 2026:

MSK reported an excess of operating revenues over expenses of $216.6 million and an operating cash flow margin of 8.9% for the first six months of 2026. These results reflect higher patient activity levels, supported by ongoing improvements in patient access and efficiencies realized through the Epic electronic health record (EHR) system.

Operating revenues increased 11.5% compared to the first six months of 2025, driven primarily by higher patient revenues and nonrecurring revenue items, including COVID Relief funding and payor settlement payments. Excluding these one-time nonrecurring items, operating revenues increased 9.9%.

Adjusted operating expenses, which exclude incremental costs associated with Epic system implementation, increased 7.0%. The increase was driven by higher personnel costs and pharmaceutical expenses, consistent with increased patient activity levels and industrywide increases in drug prices.

MSK remains focused on advancing a long-term financial strategy centered on expanding patient access, strengthening operational discipline, and supporting the Institution's mission-driven growth amid continued cost pressures across the healthcare sector.

For more information, please see instructions to access our financial disclosure report available at https://www.dacbond.com/ or https://www.mskcc.org/public-notices/financial-information.